Stock listing
NASDAQ:ANIX Anixa Biosciences, Inc. Stock
Home listing (NASDAQ) of Anixa Biosciences, Inc.
Follow Anixa Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ANIX
$2.44 USD -0.27 (-10.0%)
Close on Nov 20, 2026
- Day range
- $2.40 – $2.59 USDNov 20, 2026
- Volume
- 355,051 sharesNov 20, 2026
- Market cap
- $84.82M USDAt the close on Nov 20, 2026 · price × 34.76M shares outstanding
- 52-week range
- $2.32 – $5.46 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $827,423 USDMedian day 277,549 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ANIX · Home | $2.44 USD | -0.27 (-10.0%) | 355,051 | $2.55 | $2.59 | $2.40 | $2.71 | Close on Nov 20, 2026 |
| Frankfurt:CY71 | €2.335 EUR | -0.12 (-4.9%) | — | €2.335 | €2.335 | €2.335 | €2.455 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANIX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.44 | -0.27 | -10.0% | $2.55 | $2.59 | $2.40 | 355,051 | |
| $2.71 | +0.04 | +1.5% | $2.70 | $2.83 | $2.64 | 287,727 | |
| $2.67 | +0.12 | +4.7% | $2.55 | $2.72 | $2.55 | 228,036 | |
| $2.55 | -0.07 | -2.7% | $2.61 | $2.697 | $2.54 | 123,930 | |
| $2.62 | -0.06 | -2.2% | $2.71 | $2.72 | $2.57 | 278,633 | |
| $2.68 | -0.10 | -3.6% | $2.72 | $2.845 | $2.66 | 276,085 | |
| $2.78 | -0.28 | -9.2% | $3.07 | $3.11 | $2.77 | 277,549 | |
| $3.06 | -0.10 | -3.2% | $3.14 | $3.18 | $3.04 | 155,571 | |
| $3.16 | -0.015 | -0.5% | $3.21 | $3.30 | $3.094 | 126,713 | |
| $3.175 | +0.145 | +4.8% | $3.02 | $3.175 | $2.99 | 121,587 | |
| $3.03 | -0.25 | -7.6% | $3.27 | $3.27 | $3.00 | 201,025 | |
| $3.28 | +0.225 | +7.4% | $3.11 | $3.32 | $3.05 | 218,312 | |
| $3.055 | +0.065 | +2.2% | $3.04 | $3.19 | $3.02 | 149,606 | |
| $2.99 | -0.13 | -4.2% | $3.14 | $3.151 | $2.99 | 128,338 | |
| $3.12 | -0.18 | -5.5% | $3.28 | $3.35 | $3.10 | 140,407 | |
| $3.30 | -0.07 | -2.1% | $3.40 | $3.439 | $3.28 | 135,738 | |
| $3.37 | +0.09 | +2.7% | $3.26 | $3.43 | $3.20 | 251,324 | |
| $3.28 | +0.35 | +11.9% | $2.95 | $3.34 | $2.945 | 497,331 | |
| $2.93 | -0.06 | -2.0% | $2.94 | $2.98 | $2.90 | 135,562 | |
| $2.99 | +0.21 | +7.6% | $2.80 | $3.14 | $2.74 | 326,677 | |
| $2.78 | +0.07 | +2.6% | $2.70 | $2.78 | $2.68 | 154,000 | |
| $2.71 | +0.03 | +1.1% | $2.68 | $2.75 | $2.66 | 115,700 | |
| $2.68 | +0.07 | +2.7% | $2.64 | $2.75 | $2.64 | 163,100 | |
| $2.61 | -0.06 | -2.2% | $2.67 | $2.69 | $2.60 | 91,300 | |
| $2.67 | -0.11 | -4.0% | $2.79 | $2.82 | $2.65 | 123,400 | |
| $2.78 | +0.12 | +4.5% | $2.66 | $2.79 | $2.63 | 223,300 | |
| $2.66 | -0.01 | -0.4% | $2.75 | $2.82 | $2.63 | 228,400 | |
| $2.67 | -0.17 | -6.0% | $2.84 | $2.84 | $2.66 | 175,400 | |
| $2.84 | -0.06 | -2.1% | $2.90 | $2.92 | $2.83 | 97,700 | |
| $2.90 | -0.01 | -0.3% | $2.93 | $2.96 | $2.86 | 217,900 | |
| $2.91 | -0.04 | -1.4% | $2.93 | $2.93 | $2.86 | 259,600 | |
| $2.95 | -0.07 | -2.3% | $3.01 | $3.06 | $2.93 | 245,200 | |
| $3.02 | +0.07 | +2.4% | $2.95 | $3.11 | $2.87 | 344,900 | |
| $2.95 | 0.00 | 0.0% | $2.98 | $2.99 | $2.88 | 369,300 | |
| $2.95 | +0.18 | +6.5% | $2.83 | $2.95 | $2.77 | 433,300 | |
| $2.77 | -0.16 | -5.5% | $2.93 | $2.93 | $2.74 | 290,400 | |
| $2.93 | +0.08 | +2.8% | $2.85 | $2.95 | $2.81 | 428,900 | |
| $2.85 | +0.06 | +2.2% | $2.79 | $2.85 | $2.72 | 183,200 | |
| $2.79 | +0.01 | +0.4% | $2.78 | $2.83 | $2.70 | 305,500 | |
| $2.78 | 0.00 | 0.0% | $2.85 | $2.87 | $2.69 | 360,800 | |
| $2.78 | +0.03 | +1.1% | $2.74 | $2.81 | $2.72 | 257,700 | |
| $2.75 | -0.04 | -1.4% | $2.77 | $2.81 | $2.62 | 391,100 | |
| $2.79 | +0.09 | +3.3% | $2.73 | $2.79 | $2.68 | 434,100 | |
| $2.70 | -0.07 | -2.5% | $2.82 | $2.82 | $2.66 | 476,300 | |
| $2.77 | +0.01 | +0.4% | $2.78 | $2.79 | $2.69 | 315,200 | |
| $2.76 | +0.16 | +6.2% | $2.66 | $2.76 | $2.64 | 345,600 | |
| $2.60 | -0.09 | -3.3% | $2.70 | $2.72 | $2.56 | 557,400 | |
| $2.69 | -0.11 | -3.9% | $2.80 | $2.80 | $2.66 | 353,700 | |
| $2.80 | +0.04 | +1.4% | $2.79 | $2.88 | $2.76 | 376,400 | |
| $2.76 | +0.01 | +0.4% | $2.87 | $2.88 | $2.72 | 389,300 | |
| $2.75 | -0.08 | -2.8% | $2.76 | $2.81 | $2.66 | 400,100 | |
| $2.83 | -0.07 | -2.4% | $2.92 | $2.97 | $2.79 | 476,600 | |
| $2.90 | -0.17 | -5.5% | $3.10 | $3.20 | $2.88 | 441,200 | |
| $3.07 | +0.02 | +0.7% | $3.03 | $3.11 | $3.00 | 367,900 | |
| $3.05 | -0.08 | -2.6% | $3.14 | $3.25 | $2.99 | 409,100 | |
| $3.13 | -0.15 | -4.6% | $3.28 | $3.39 | $3.12 | 334,700 | |
| $3.28 | -0.07 | -2.1% | $3.41 | $3.49 | $3.23 | 342,200 | |
| $3.35 | -0.13 | -3.7% | $3.43 | $3.63 | $3.31 | 353,300 | |
| $3.48 | -0.12 | -3.3% | $3.60 | $3.67 | $3.42 | 214,700 | |
| $3.60 | -0.01 | -0.3% | $3.60 | $3.68 | $3.52 | 337,300 | |
| $3.61 | -0.05 | -1.4% | $3.64 | $3.75 | $3.47 | 291,300 | |
| $3.66 | +0.04 | +1.1% | $3.64 | $3.87 | $3.62 | 607,300 | |
| $3.62 | -0.09 | -2.4% | $3.66 | $3.73 | $3.51 | 138,800 | |
| $3.71 | +0.12 | +3.3% | $3.64 | $3.76 | $3.60 | 182,400 | |
| $3.59 | -0.12 | -3.2% | $3.69 | $3.71 | $3.55 | 168,500 |
Splits
5 splits since 1985 · NASDAQ:ANIX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 5-for-4 | Split | |
| 3-for-1 | Split |
- Ticker
- NASDAQ:ANIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 24 slides
Latest news
Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology
Nov 19, 2026
Closed $2.44 (-10.0%) on Nov 20, 2026
Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
Nov 18, 2026
Closed $2.71 (+1.5%) on Nov 18, 2026
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Nov 4, 2026
Closed $3.28 (+7.4%) on Nov 4, 2026
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Oct 26, 2026
Closed $2.93 (-2.0%) on Oct 26, 2026
Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Oct 13, 2026
Closed $2.67 (-6.0%) on Oct 13, 2026
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Oct 13, 2026
Closed $2.67 (-6.0%) on Oct 13, 2026
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Oct 5, 2026
Closed $2.95 (0.0%) on Oct 5, 2026
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Oct 1, 2026
Closed $2.77 (-5.5%) on Oct 1, 2026
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Sep 21, 2026
Closed $2.70 (-2.5%) on Sep 21, 2026
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Sep 16, 2026
Closed $2.60 (-3.3%) on Sep 16, 2026
Anixa Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 41 in the last 12 months · 186 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 18 decks · latest November 2026
Where Anixa Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ANIX · Home listing · This page | NASDAQ | United States | USD |
| gettex:CY71 | gettex | Germany | EUR |
| LS Exchange:A2N6ZF | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2N6ZF | Lang & Schwarz | Germany | EUR |
| Frankfurt:CY71 | Frankfurt | Germany | EUR |
| Tradegate:CY71 | Tradegate | Germany | EUR |
| BOATS:ANIX | BOATS | United States | USD |
| Munich:CY71 | Munich | Germany | EUR |
| Dusseldorf:CY71 | Dusseldorf | Germany | EUR |
| Hamburg:CY71 | Hamburg | Germany | EUR |
| Stuttgart:CY71 | Stuttgart | Germany | EUR |
Valuation
Price/book 5.9× against a median of 2.0×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $70.96M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.45
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Anixa Biosciences, Inc. · NASDAQ:ANIX | US$84.82M | US$70.96M | n/a | n/a | n/a | 5.9× | n/a | 0.0× | 1.45 |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Bioceltix SA · GPW:BCX | US$86.38M | US$72.43M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.43M | US$48.52M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Genome & Co. · KRX:314130 | US$85.27M | US$37.21M | n/a | 2.0× | n/a | 1.6× | −169.1% | 0.0× | n/a |
| BetterLife Pharma Inc. · CSE:BETR | US$84.03M | US$83.37M | n/a | n/a | n/a | n/a | n/a | n/a | 1.14 |
| Shine-On Biomedical Co., Ltd. · TPEX:6926 | US$83.56M | US$59.02M | n/a | 64.8× | n/a | 3.5× | −367.6% | 0.0× | n/a |
| Rallybio Corporation · NASDAQ:RLYB | US$83.29M | −US$7.40M | 3.1× | −17.1× | n/a | 0.9× | n/a | 0.0× | 0.58 |
| Median of the others | US$85.73M | US$53.77M | 3.1× | 16.2× | 2.0× | −364.5% | 0.0× | 1.31 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.67 USD · Analysts' mean
- EPS, year to Oct 2026
- -0.31 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Amit Kumar | Chairman of the Board & CEO |
| Michael Catelani | President, COO & CFO |
Board
| Director | Role |
|---|---|
| Amit Kumar | Chairman of the Board & CEO |
| Arnold Baskies | Director |
| Emily Gottschalk | Director |
| Lew Titterton | Lead Independent Director |
| Michael Catelani | President, COO & CFO |
Events
- Next results
- Jan 11, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Sep 9, 2026 · After close | −2.8% |
| Q2 2026 | Jun 10, 2026 · After close | +5.5% |
| Q1 2026 | Mar 9, 2026 · After close | 0.0% |
| Q4 2025 | Jan 7, 2026 | +7.5% |
| Q3 2025 | Sep 10, 2025 · After close | −2.3% |
| Q2 2025 | May 28, 2025 · After close | +2.8% |
| Q1 2025 | Mar 21, 2025 · After close | +1.3% |
| Q4 2024 | Jan 10, 2025 · After close | −2.7% |
| Q3 2024 | Sep 6, 2024 · After close | −1.3% |
| Q2 2024 | Jun 4, 2024 · After close | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Mar 12, 2024 · After close | +3.3% |
| Q4 2023 | Jan 16, 2024 · After close | −8.6% |
| Q3 2023 | Sep 6, 2023 · After close | −5.7% |
| Q2 2023 | Jun 14, 2023 · After close | +4.6% |
| Q1 2023 | Mar 17, 2023 · Before open | −8.9% |
| Q4 2022 | Jan 4, 2023 · After close | −3.3% |
| Q3 2022 | Sep 9, 2022 · After close | +8.7% |
| Q2 2022 | Jun 10, 2022 · After close | −9.0% |
| Q1 2022 | Mar 11, 2022 · After close | −5.6% |
| Q4 2021 | Jan 4, 2022 · After close | −9.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 24 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 24 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 23 slides | September 2026 |
| Investor Presentation (March 2026) | Investor deck | 21 slides | Mar 11, 2026 |
| Shareholder Meeting (March 2025) | Shareholder meeting | 38 slides | Mar 21, 2025 |
| Shareholder Meeting (March 2024) | Shareholder meeting | 34 slides | Mar 22, 2024 |
| Investor Presentation (March 2023) | Investor deck | 22 slides | Mar 10, 2023 |
| Technical Presentation (September 2022) | Technical | 12 slides | Sep 29, 2022 |
| Investor Presentation (March 2022) | Investor deck | 27 slides | Mar 11, 2022 |
| Investor Presentation (May 2021) | Investor deck | 16 slides | May 27, 2021 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2020) | Investor deck | 16 slides | Sep 16, 2020 |
| Investor Presentation (August 2020) | Investor deck | 19 slides | Aug 17, 2020 |
| Shareholder Meeting (October 2019) | Shareholder meeting | 23 slides | Oct 24, 2019 |
| Investor Presentation (August 2019) | Investor deck | 22 slides | Aug 21, 2019 |
| Investor Presentation (May 2019) | Investor deck | 22 slides | May 23, 2019 |
| ITUS — Shareholder Meeting (September 2018) | Shareholder meeting | 15 slides | Sep 27, 2018 |
| ITUS — Investor Presentation (June 2017) | Investor deck | 25 slides | Jun 2, 2017 |
| Copytele — Investor Presentation (October 2012) | Investor deck | 13 slides | Oct 10, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210.0K | 210.0K | 512.0K | 250.0K | 1.11M | 362.5K | 300.0K | |||
| Research and development | 5.07M | 6.40M | 4.77M | 6.70M | 6.19M | 4.38M | 5.47M | 6.81M | 1.60M | 1.56M |
| Selling, general and administrative | 5.66M | 6.91M | 4.41M | 2.71M | ||||||
| Operating income | -11.7M | -13.8M | -11.0M | -13.9M | -13.1M | -9.98M | -11.9M | -14.3M | -6.08M | -4.51M |
| Depreciation and amortization | 38.3K | 47.6K | 18.4K | 43.2K | 33.3K | |||||
| EBITDA | -9.94M | -11.8M | -14.3M | -6.03M | -4.48M | |||||
| Interest expense | 500.5K | 519.9K | ||||||||
| Income before tax | -11.8M | -14.2M | -5.01M | -5.02M | ||||||
| Net income | -10.9M | -12.6M | -9.81M | -13.6M | -13.0M | -10.0M | -11.6M | -14.0M | -5.01M | -5.02M |
| Earnings per share, basic | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | -0.45 | -0.59 | -0.79 | -0.58 | -0.57 |
| Earnings per share, diluted | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | -0.45 | -0.59 | -0.79 | -0.58 | -0.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.24M | 1.27M | 915.0K | 12.4M | 29.1M | 6.42M | 3.49M | 3.06M | 3.34M | 2.49M |
| Short-term investments | 13.9M | 18.7M | 22.9M | 17.3M | 6.60M | 2.64M | 2.35M | 2.00M | 3.50M | 750.0K |
| Receivables | 173.0K | 270.0K | 46.0K | 2.23K | 66.5K | 307.0K | ||||
| Current assets | 15.9M | 21.4M | 25.4M | 30.2M | 36.0M | 9.37M | 6.09M | 5.54M | 7.01M | 3.40M |
| Property, plant and equipment | 200.6K | 72.7K | 52.7K | 156.6K | ||||||
| Total assets | 16.1M | 21.6M | 25.5M | 30.4M | 36.3M | 9.45M | 6.29M | 6.45M | 8.81M | 5.63M |
| Accounts payable | 165.0K | 525.0K | 206.0K | 265.0K | 136.0K | 232.4K | 585.8K | 582.0K | 480.3K | 373.2K |
| Current liabilities | 1.97M | 2.50M | 2.03M | 2.04M | 1.27M | 1.19M | 1.48M | 1.27M | 889.5K | 468.8K |
| Total liabilities | 2.13M | 2.70M | 2.15M | 2.21M | 1.49M | 1.19M | 1.48M | 889.5K | 4.64M | |
| Shareholders' equity | 15.2M | 20.0M | 24.3M | 29.0M | 35.4M | 8.76M | 5.24M | 5.43M | 7.92M | 987.5K |
| Shares outstanding | 33.0M | 32.2M | 31.1M | 30.9M | 30.1M | 24.2M | 20.3M | 18.9M | 16.6M | 8.75M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.17M | -7.33M | -6.21M | -6.49M | -4.94M | -6.18M | -4.74M | -4.27M | -3.80M | -3.38M |
| Capital spending | -15.8K | -175.5K | -38.4K | -30.2K | -146.5K | |||||
| Free cash flow | -6.19M | -4.92M | -4.31M | -3.83M | -3.53M | |||||
| Cash from investing | 4.87M | 4.28M | -5.60M | -10.7M | -3.92M | -305.8K | -525.5K | 1.46M | -2.74M | 1.50M |
| Cash from financing | 2.28M | 3.42M | 366.0K | 452.0K | 31.6M | 9.41M | 5.70M | 2.53M | 7.38M | -2.68K |
| Share buybacks | -6.00K | |||||||||
| Change in cash | -27.0K | 356.0K | -11.4M | -16.8M | 22.7M | 2.93M | 435.7K | -283.5K | 851.1K | -1.88M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Sep 9, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Mar 11, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Mar 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jan 28, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Jan 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Jan 12, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 16, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 10, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 10, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 28, 2025 | Quarterly report | SEC |
| 8-K · Current report | Mar 21, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Mar 11, 2025 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Feb 6, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 10, 2025 | Offer document | SEC |
| 10-K · Annual report | Jan 10, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Sep 6, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Material contract | SEC |
| SC 13D · Big-stake notice | May 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 22, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Mar 12, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Feb 8, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 16, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 16, 2024 | Offer document | SEC |
| 10-K · Annual report | Jan 16, 2024 | Annual report | SEC |
| 8-K · Current report | Dec 7, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Sep 6, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 14, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Mar 16, 2023 | Quarterly report | SEC |
| 8-K · Current report | Mar 10, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jan 27, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 4, 2023 | Offer document | SEC |
| 10-K · Annual report | Jan 4, 2023 | Annual report | SEC |
| 8-K · Current report | Dec 8, 2022 | Current report | SEC |
| 4 · Change in ownership | Nov 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2022 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 20, 2022 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2022 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Sep 15, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 14, 2022 | Other filings | SEC |
| DEL AM | Sep 12, 2022 | Other filings | SEC |
| S-3 · Registration statement | Sep 9, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 17, 2022 | Current report | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 10, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | May 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2022 | Management or board change | SEC |
| 8-K · Current report | Mar 11, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Mar 11, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Jan 28, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2022 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 4, 2022 | Offer document | SEC |
| 10-K · Annual report | Jan 4, 2022 | Annual report | SEC |
| 8-K · Current report | Dec 9, 2021 | Current report | SEC |
| 4 · Change in ownership | Nov 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2021 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2021 | Current report | SEC |
| 8-K · Current report | Oct 4, 2021 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 3, 2021 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Sep 1, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 28, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2021 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Jun 10, 2021 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 10, 2021 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2021 | Insider trade | SEC |
| 8-K · Current report | May 27, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | May 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2021 | Insider trade | SEC |
| DEF 14A · Proxy statement | Apr 9, 2021 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2021 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Mar 30, 2021 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 26, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2021 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Mar 24, 2021 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 22, 2021 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 22, 2021 | Offer document | SEC |
| 424B5 · Prospectus | Mar 22, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Mar 11, 2021 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 5, 2021 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2021 | Insider trade | SEC |
This page holds 200 of 983 filings. Open Filings
Cap table
Built by 6ix from Anixa Biosciences, Inc.’s releases · as of Sep 9, 2026
- Common shares
- 34,763,802
- Fully diluted
- 34,763,802
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 34,763,802 | Sep 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 9, 2026 | 34,763,802 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amit Kumar Other companies: Aeolus Pharmaceuticals Inc (Board Member · Since at least Nov 14, 2026) | Chief Executive Officer, Director · Since at least May 8, 2018 |
| David C. Cavalier Other companies: Aeolus Pharmaceuticals Inc (Chairman · Since at least Jul 27, 2007) | Director · Sep 27, 2018 – Aug 13, 2020 · Past |
| John Monahan Other companies: Theriva Biologics, Inc. (Director · Since at least Nov 11, 2020) | Director · Aug 23, 2016 – Aug 13, 2020 · Past |
| Lewis H Titterton Jr Other companies: ParkerVision, Inc. (Director · Since at least Jun 22, 2023) | Director · Since at least Apr 26, 2022 |
| Robert Berman Other companies: enVVeno Medical Corporation (Chief Executive Officer and Director · Since at least May 30, 2018) | President & CEO, Director · Jul 1, 2013 – Jun 2, 2017 · Past |
| Arnold Baskies | Director · Since at least Sep 27, 2018 |
| Emily Gottschalk | Director · Since at least Nov 5, 2026 |
| Frank J Disanto | President, Director · Oct 6, 2006 – Nov 12, 2007 · Past |
| George P Larounis | Director · Oct 26, 2011 – Sep 5, 2012 · Past |
| John H Roop | Sr. Vice President-Engineering · Sep 19, 2012 – Jan 24, 2014 · Past |
All 12 people
| Person | Seat |
|---|---|
| Lew Titterton | Lead Independent Director · Since at least Oct 26, 2026 |
| Michael Catelani | President, COO & CFO · Since at least Apr 14, 2022 |
Log in to ask 6ix AI your own questions about Anixa Biosciences, Inc.